Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2458657 | 0.84 | TSHR (0.55) | TSHRKDM4EHSD17B10MAPK1SMN1; SMN2 | |
| SCHEMBL4628672 | 0.84 | TSHR (0.60) | TSHRKDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL10562029 | 0.83 | TSHR (0.57) | TSHRKDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL30755337 | 0.83 | TSHR (0.57) | TSHRKDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL2453339 | 0.83 | TSHR (0.53) | TSHRKDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL1997075 | 0.83 | TSHR (0.60) | TSHRKDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL5230827 | 0.81 | CA12 (0.57) | TSHRKDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL11933660 | 0.81 | TSHR (0.56) | TSHRKDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL3895996 | 0.81 | CA12 (0.70) | TSHRKDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL10512113 | 0.81 | SLC6A4 (0.47) | TSHRKDM4EHPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102131791-B | Dibenzothiepiazane derivatives and their use | ASTRAZENECA SWEDEN AB | 2014-12-24 | — | — | CN | claimed |
| US-8653257-B2 | Dibenzothiazepine derivatives and uses thereof—424 | ASTRAZENECA AB (SE) | 2014-02-18 | — | — | US | claimed |
| US-20120202991-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF - 424 | ASTRAZENECA AB (SE) | 2012-08-09 | — | — | US | claimed |
| US-11548894-B2 | Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-01-10 | — | — | US | disclosed |
| US-20190263820-A1 | BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-08-29 | — | — | US | disclosed |
| US-10112948-B2 | Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-10-30 | — | — | US | disclosed |
| EP-2935257-B1 | CYCLIC SULFONAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2018-02-07 | — | — | EP | disclosed |
| US-9714252-B2 | Cyclic sulfonamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714252-B2 | Cyclic sulfonamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170114062-A1 | BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-04-27 | — | — | US | disclosed |
| WO-2017007634-A1 | BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-01-12 | — | — | WO | disclosed |
| US-20080090854-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| WO-2007117381-A9 | 2 -AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2008-03-27 | — | — | WO | disclosed |
| CN-101094830-A | Fused bicyclic carboxamide derivatives for use as CXCR2 inhibitors in the treatment of inflammation | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-12-26 | — | — | CN | disclosed |
| WO-2007117381-A2 | 2 -AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070105819-A1 | CB-1 modulating compounds and their use | ACADIA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
| US-20070105819-A1 | CB-1 modulating compounds and their use | ACADIA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
| US-20070105819-A1 | CB-1 modulating compounds and their use | ACADIA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
| WO-2007047737-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047737-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105819-A1 | CB-1 modulating compounds and their use | CNR1, CNR2, FAAH | TSHR 1641/4885KDM4E 2248/4885HPGD 726/4885 |
| US-10112948-B2 | Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers | ACAT1, ACAT2, NPC1L1 | TSHR 4433/4885KDM4E 2008/4885HPGD 1744/4885 |
| US-20190263820-A1 | BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS | ACAT1, ACAT2, NPC1L1 | TSHR 4433/4885KDM4E 2008/4885HPGD 1744/4885 |
| US-11548894-B2 | Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers | ACAT1, ACAT2, NPC1L1 | TSHR 4433/4885KDM4E 2008/4885HPGD 1744/4885 |
| US-20080090854-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | TSHR 1709/4885KDM4E 3892/4885HPGD 565/4885 |
| US-20170114062-A1 | BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS | ACAT1, ACAT2, NPC1L1 | TSHR 4433/4885KDM4E 2008/4885HPGD 1744/4885 |
| US-20120202991-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF - 424 | DRD4, DRD2, GABBR1 | TSHR 678/4885KDM4E 1453/4885HPGD 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.